News und Analysen
Toshiba Tec Introducing e-BRIDGE Next Updates
Toshiba Tec Corporation (TOKYO: 6588) will launch an updated version of its MFP platform e-BRIDGE Next on June 25th, 2021, adding new features to the current lineup of Toshiba MFPs. These features
Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press
Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press
Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press
Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press
Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press
Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press
Panasonic Accelerates the Autonomous Supply Chain with Acquisition of Blue Yonder
Panasonic Corporation announced today that it has agreed to acquire Blue Yonder, the leading end-to-end, digital fulfillment platform provider. Panasonic will purchase the remaining 80% of shares
Panasonic Accelerates the Autonomous Supply Chain with Acquisition of Blue Yonder
Panasonic Corporation announced today that it has agreed to acquire Blue Yonder, the leading end-to-end, digital fulfillment platform provider. Panasonic will purchase the remaining 80% of shares
Panasonic Accelerates the Autonomous Supply Chain with Acquisition of Blue Yonder
Panasonic Corporation announced today that it has agreed to acquire Blue Yonder, the leading end-to-end, digital fulfillment platform provider. Panasonic will purchase the remaining 80% of shares
Panasonic Accelerates the Autonomous Supply Chain with Acquisition of Blue Yonder
Panasonic Corporation announced today that it has agreed to acquire Blue Yonder, the leading end-to-end, digital fulfillment platform provider. Panasonic will purchase the remaining 80% of shares
Panasonic Accelerates the Autonomous Supply Chain with Acquisition of Blue Yonder
Panasonic Corporation announced today that it has agreed to acquire Blue Yonder, the leading end-to-end, digital fulfillment platform provider. Panasonic will purchase the remaining 80% of shares
Panasonic Accelerates the Autonomous Supply Chain with Acquisition of Blue Yonder
Panasonic Corporation announced today that it has agreed to acquire Blue Yonder, the leading end-to-end, digital fulfillment platform provider. Panasonic will purchase the remaining 80% of shares
Nitto stärkt das Geschäft zur Herstellung von Oligonukleotid-Therapeutika
Als Reaktion auf die schnelle Marktexpansion von Oligonukleotid-Therapeutika, die das Potenzial haben, sowohl verbreitete als auch schwer heilbare Krankheiten zu behandeln, wird die Nitto Denko
Nitto stärkt das Geschäft zur Herstellung von Oligonukleotid-Therapeutika
Als Reaktion auf die schnelle Marktexpansion von Oligonukleotid-Therapeutika, die das Potenzial haben, sowohl verbreitete als auch schwer heilbare Krankheiten zu behandeln, wird die Nitto Denko
Nitto stärkt das Geschäft zur Herstellung von Oligonukleotid-Therapeutika
Als Reaktion auf die schnelle Marktexpansion von Oligonukleotid-Therapeutika, die das Potenzial haben, sowohl verbreitete als auch schwer heilbare Krankheiten zu behandeln, wird die Nitto Denko
Nitto stärkt das Geschäft zur Herstellung von Oligonukleotid-Therapeutika
Als Reaktion auf die schnelle Marktexpansion von Oligonukleotid-Therapeutika, die das Potenzial haben, sowohl verbreitete als auch schwer heilbare Krankheiten zu behandeln, wird die Nitto Denko
Nitto stärkt das Geschäft zur Herstellung von Oligonukleotid-Therapeutika
Als Reaktion auf die schnelle Marktexpansion von Oligonukleotid-Therapeutika, die das Potenzial haben, sowohl verbreitete als auch schwer heilbare Krankheiten zu behandeln, wird die Nitto Denko
Nitto stärkt das Geschäft zur Herstellung von Oligonukleotid-Therapeutika
Als Reaktion auf die schnelle Marktexpansion von Oligonukleotid-Therapeutika, die das Potenzial haben, sowohl verbreitete als auch schwer heilbare Krankheiten zu behandeln, wird die Nitto Denko
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President:
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President:
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President:
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President:
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President:
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: